$3.37
6.98% today
Nasdaq, Apr 04, 09:17 pm CET
ISIN
US3441741077
Symbol
FHTX
Sector
Industry

Foghorn Therapeutics Inc Stock price

$3.15
-1.17 27.08% 1M
-4.33 57.89% 6M
-1.57 33.26% YTD
-4.06 56.31% 1Y
-13.24 80.78% 3Y
-12.85 80.31% 5Y
-12.85 80.31% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-0.27 7.89%
ISIN
US3441741077
Symbol
FHTX
Sector
Industry

Key metrics

Market capitalization $175.18m
Enterprise Value $-31.44m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.31
EV/Sales (TTM) EV/Sales -1.39
P/S ratio (TTM) P/S ratio 7.75
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -33.83%
Revenue (TTM) Revenue $22.60m
EBIT (operating result TTM) EBIT $-100.29m
Free Cash Flow (TTM) Free Cash Flow $-101.31m
Cash position $243.75m
EPS (TTM) EPS $-1.69
P/E forward negative
P/S forward 6.85
EV/Sales forward negative
Short interest 2.76%
Show more

Is Foghorn Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Foghorn Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Foghorn Therapeutics Inc forecast:

5x Buy
100%

Analyst Opinions

5 Analysts have issued a Foghorn Therapeutics Inc forecast:

Buy
100%

Financial data from Foghorn Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
23 23
34% 34%
100%
- Direct Costs 3.10 3.10
48% 48%
14%
20 20
31% 31%
86%
- Selling and Administrative Expenses 25 25
6% 6%
112%
- Research and Development Expense 91 91
14% 14%
405%
-97 -97
5% 5%
-430%
- Depreciation and Amortization 3.10 3.10
48% 48%
14%
EBIT (Operating Income) EBIT -100 -100
7% 7%
-444%
Net Profit -87 -87
12% 12%
-383%

In millions USD.

Don't miss a Thing! We will send you all news about Foghorn Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Foghorn Therapeutics Inc Stock News

Neutral
GlobeNewsWire
10 days ago
- FHD-909 (LY4050784) advancing in an ongoing Phase 1 trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population
Neutral
GlobeNewsWire
29 days ago
First-in-class oral selective SMARCA2 (BRM) inhibitor FHD-909 (LY4050784) continues enrollment in Phase 1 trial for SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population
Neutral
GlobeNewsWire
about one month ago
CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the B. Riley Securities Precision Oncology and Radiopharma Conference, and at the TD Cowen 45th Annual Heal...
More Foghorn Therapeutics Inc News

Company Profile

Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. It is discovering and developing a novel class of precision medicine therapeutics targeting the chromatin regulatory system in oncology. Through its scalable Gene Traffic Control product platform, the firm is systematically interrogating and drugging the chromatin regulatory system. The company was founded by Cigall Kadoch, Gerald W. Crabtree and Douglas G. Cole in October 2015 and is headquartered in Cambridge, MA.

Head office United States
CEO Adrian Gottschalk
Employees 112
Founded 2015
Website www.foghorntx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today